<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37927">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612779</url>
  </required_header>
  <id_info>
    <org_study_id>CA204-142</org_study_id>
    <nct_id>NCT02612779</nct_id>
  </id_info>
  <brief_title>A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.</brief_title>
  <official_title>A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort)
      and elotuzumab in combination with nivolumab (EN Cohort) to assess the safety and efficacy
      of these combination therapies for treatment of relapsed or refractory MM patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EPd cohort: Progression Free Survival (PFS)</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>PFS is defined as the time from first dosing date to the date of the first documented progression per IMWG uniform criteria or death due to any cause, whichever occurs first</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EN Cohort: Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>ORR is defined as proportion of subjects with a best overall response of partial response (PR) or better</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EPd Cohort: Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>ORR is defined as proportion of subjects with a best overall response of partial response (PR) or better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EPd Cohort: Overall Survival Rate (OS)</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>OS is defined as the time from first dosing date to the date of death from any cause. A subject who has not died will be censored at last known date alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EN Cohort: Progression Free Survival (PFS)</measure>
    <time_frame>Approximately 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Elotuzumab + Pomalidamide + Low Dose Dexamethasone (EPd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive treatment with elotuzumab in combination with pomalidomide and low-dose dexamethasone. Patients are eligible to receive Nivolumab at progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elotuzumab + Nivolumab (EN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive treatment with a combination of elotuzumab and nivolumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elotuzumab</intervention_name>
    <arm_group_label>Elotuzumab + Pomalidamide + Low Dose Dexamethasone (EPd)</arm_group_label>
    <arm_group_label>Elotuzumab + Nivolumab (EN)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <arm_group_label>Elotuzumab + Pomalidamide + Low Dose Dexamethasone (EPd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Elotuzumab + Pomalidamide + Low Dose Dexamethasone (EPd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Elotuzumab + Pomalidamide + Low Dose Dexamethasone (EPd)</arm_group_label>
    <arm_group_label>Elotuzumab + Nivolumab (EN)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          1. All subjects must have documented disease progression per IMWG criteria during or
             after their last anti-myeloma therapy.

          2. ECOG Performance Status less than or equal to 2

          3. Subject Re-enrollment: This study permits the re-enrollment of a subject that has
             discontinued the study as a pre-treatment failure (ie, has not been treated). If
             re-enrolled, the subject must be re-consented.

          4. EPd Cohort:

               -  must have received at least 1 but no greater than 2 prior lines of therapy
                  (note: induction and stem cell transplants with or without maintenance therapy
                  is considered 1 line of therapy)

               -  Subjects must have received prior treatment with a lenalidomide-containing
                  regimen for at least 2 consecutive cycles (full therapeutic dose) and must have
                  been deemed as relapsed, refractory, or intolerant. Refractory is defined as
                  progressing on-treatment or within 60 days of the last dose.

          5. EN Cohort:

               -  Subjects must have received at least 3 prior lines of therapy including a
                  proteasome inhibitor (PI) and an immunomodulatory (IMID) agent OR were
                  double-refractory to both an IMID and a PI. Refractory is defined as progressing
                  on-treatment or within 60 days of the last dose.

        Exclusion Criteria:

          1. Subjects with solitary bone or extramedullary plasmacytoma as the only evidence of
             plasma cells dyscrasia

          2. Subjects with monoclonal gammopathy of undetermined significance (MGUS), smoldering
             multiple myeloma (SMM), primary amyloidosis, Waldenstrom's macroglobulinemia, or
             POEMS syndrome (plasma cell dyscrasia with poly neuropathy, organomegaly,
             endocrinopathy, monoclonal protein, and skin changes)

          3. Subjects with Central Nervous System involvement with multiple myeloma

        Other protocol defined inclusion/exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southern Cancer Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Meshad, Site 0025</last_name>
      <phone>251-607-5284</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sansum Clinic - Usor</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Greenwald, Site 0015</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Matous, Site 0014</last_name>
      <phone>720-754-4896</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers (Williams) - Usor</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Rifkin, Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scri Florida Cancer Specialists East</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shachar Peles, Site 0003</last_name>
      <phone>561-472-1696</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhuri Bajaj, Site 0005</last_name>
      <phone>309-243-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bay Hematology Oncology</name>
      <address>
        <city>Easton</city>
        <state>Maryland</state>
        <zip>21601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo Erlich, Site 0008</last_name>
      <phone>410-820-5945</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Cole, Site 0019</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Zonder, Site 0023</last_name>
      <phone>313-576-8395</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School Of Medicine, Siteman Cancer Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravi Vij, Site 0022</last_name>
      <phone>314-747-6502</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sundar Jagannath, Site 0001</last_name>
      <phone>212-241-7846</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Fanning, Site 0006</last_name>
      <phone>864-241-6251</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avera Health Care</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Galal, Site 0013</last_name>
      <phone>605-322-3086</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jones Clinic Pc</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scri Tennessee Oncology Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Berdeja, Site 0007</last_name>
      <phone>615-329-7274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology (Loop) - Usor</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allyson Harroff, Site 0010</last_name>
      <phone>210-656-7177</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists (Leesburg) - Usor</name>
      <address>
        <city>Leesburg</city>
        <state>Virginia</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Orloff, Site 0017</last_name>
      <phone>703-280-5390</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Bensinger, Site 0012</last_name>
      <phone>206-215-2397</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest</name>
      <address>
        <city>Spokane Valley</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danko Martincic, Site 0020</last_name>
      <phone>509-474-4314</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aurora Health Care</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Thompson, Site 0021</last_name>
      <phone>414-778-4345</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>November 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
